Equities research analysts forecast that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will announce $1.91 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Celldex Therapeutics’ earnings, with the lowest sales estimate coming in at $1.70 million and the highest estimate coming in at $2.11 million. Celldex Therapeutics posted sales of $1.87 million during the same quarter last year, which indicates a positive year over year growth rate of 2.1%. The firm is expected to issue its next earnings results on Tuesday, March 13th.

On average, analysts expect that Celldex Therapeutics will report full year sales of $1.91 million for the current fiscal year, with estimates ranging from $11.00 million to $11.40 million. For the next fiscal year, analysts forecast that the firm will post sales of $20.30 million per share, with estimates ranging from $6.50 million to $34.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07. The firm had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The company’s quarterly revenue was up 77.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.29) EPS.

Several equities research analysts have weighed in on the stock. WBB Securities restated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Celldex Therapeutics currently has a consensus rating of “Hold” and an average target price of $7.05.

Several large investors have recently modified their holdings of CLDX. Vanguard Group Inc. grew its position in shares of Celldex Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares during the period. Geode Capital Management LLC grew its position in shares of Celldex Therapeutics by 12.5% during the 1st quarter. Geode Capital Management LLC now owns 883,786 shares of the biopharmaceutical company’s stock worth $3,190,000 after buying an additional 98,114 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Celldex Therapeutics by 426.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock worth $1,778,000 after buying an additional 398,978 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Celldex Therapeutics by 23.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 510,036 shares of the biopharmaceutical company’s stock worth $1,842,000 after buying an additional 95,544 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Celldex Therapeutics by 7.9% during the 1st quarter. Bank of America Corp DE now owns 134,133 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 9,865 shares during the period. Institutional investors own 52.55% of the company’s stock.

Celldex Therapeutics (NASDAQ:CLDX) traded up $0.10 on Friday, reaching $3.03. 1,693,031 shares of the company’s stock traded hands, compared to its average volume of 915,290. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $4.07.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/09/brokerages-anticipate-celldex-therapeutics-inc-cldx-will-post-quarterly-sales-of-1-91-million.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.